Institutional members access full text with Ovid®

Share this article on:

Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel

Fernández, Ovidioa; Afonso, Javierb; Vázquez, Sergioe; Campos, Begoñae; Lázaro, Matínf; León, Luisc; Antón Aparicio, Luis M.d

doi: 10.1097/CAD.0000000000000045
Review Article

Docetaxel is the standard first-line chemotherapy for men with metastatic castration-resistant prostate cancer. Until recently, there was no standard therapy after failure of docetaxel treatment. Cabazitaxel has been shown to improve overall survival in this setting. As a result, the treatment paradigm for mCRPC is changing rapidly. The improved survival shown with cabazitaxel provides an important new opportunity to treat men with mCRPC after docetaxel treatment. Despite the toxicity recorded in the pivotal study, subsequent trials have shown that cabazitaxel is a safe drug. Patient selection and the optimal interval between prior docetaxel treatment and cabazitaxel remain the critical issues. According to a subanalysis of the various studies discussed in this review, there is a patient profile that will probably benefit from use of cabazitaxel after docetaxel failure. Cabazitaxel represents a new treatment option for patients with prostate cancer.

aOncology Service, Ourense’s Hospital Complex, Ourense

bMedical Oncology Service, Arquitecto Marcide’s University Hospital

cMedical Oncology Service, Santiago's University Clinical Hospital

dMedical Oncology Service, A Coruña's University Hospital Complex, A Coruña

eMedical Oncology Service, Lucus Augusti’s University Hospital, Lugo

fMedical Oncology Service, Xeral Cies de Vigo’s University Hospital Complex, Pontevedra, Spain

Correspondence to Ovidio Fernández, Oncology Service, Ourense’s Hospital Complex, Ramón Puga N°54, 32005 Ourense, Spain Tel: +34 988 385 471; fax: +34 988 372 306; e-mail:

Received May 24, 2013

Accepted October 4, 2013

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins